Breaking News Instant updates and real-time market news.

MD

Mednax

$51.30

1.51 (3.03%)

12:18
12/01/17
12/01
12:18
12/01/17
12:18

Mednax tells Bloomberg no bank retained for sales process

Mednax told Bloomberg that it has not retained an investment bank for any sales process.

  • 06

    Dec

MD Mednax
$51.30

1.51 (3.03%)

09/17/17
KEYB
09/17/17
UPGRADE
Target $51
KEYB
Overweight
MEDNAX upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jason Gurda upgraded MEDNAX to Overweight with a $51 price target. Gurda expects a moderation in operating headwinds over the next few quarters, cost cutting/new revenue to offset some of the headwinds, thinks the radiology business is poised for strong growth, and views the company as a potential acquisition target over the next few years.
09/18/17
KEYB
09/18/17
UPGRADE
Target $51
KEYB
Overweight
Mednax upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jason Gurda upgraded Mednax to Overweight with a $51 price target. The analyst sees the company's operating headwinds moderating over the next few quarters and growth in its third specialty, radiology, accelerating in the the near-term. He thinks the shares at current levels are "relatively inexpensive."
09/18/17
09/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Caterpillar (CAT) upgraded to Buy from Neutral at UBS with analyst Steven Fisher saying his firm's latest analysis of private non-residential construction ex-Power shows a re-acceleration in activity in the fourth quarter and mid-single digit growth into 2018. 2. Mednax (MD) upgraded to Overweight from Sector Weight at KeyBanc analyst Jason Gurda saying he sees the company's operating headwinds moderating over the next few quarters and growth in its third specialty, radiology, accelerating in the the near-term. 3. Infosys (INFY) upgraded to Neutral from Sell at Goldman Sachs with the firm saying management uncertainty and guidance risk is already priced in. 4. Klondex Mines (KLDX) upgraded to Buy from Hold at Canaccord. 5. BP (BP) upgraded to Outperform from Market Perform at BMO Capital with analyst Brendan Warn saying he thinks the company's free cash flow will be boosted by "delivery of new upstream volumes, premium downstream product demand and improving (refining marker margin)." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/17
BMOC
10/16/17
INITIATION
Target $46
BMOC
Market Perform
Mednax initiated with a Market Perform at BMO Capital
BMO Capital analyst Matt Borsch initiated Mednax with an Market Perform and $46 price target due to unfavorable macroeconomic factors coupled with a slower-paced acquisition pipeline could lead to additional near-term volatility in financial results.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.